GPCR vs. EWTX, HRMY, KURA, SDGR, TARO, NAMS, SNDX, RCUS, LGND, and ARDX
Should you be buying Structure Therapeutics stock or one of its competitors? The main competitors of Structure Therapeutics include Edgewise Therapeutics (EWTX), Harmony Biosciences (HRMY), Kura Oncology (KURA), Schrödinger (SDGR), Taro Pharmaceutical Industries (TARO), NewAmsterdam Pharma (NAMS), Syndax Pharmaceuticals (SNDX), Arcus Biosciences (RCUS), Ligand Pharmaceuticals (LGND), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical preparations" industry.
Edgewise Therapeutics (NASDAQ:EWTX) and Structure Therapeutics (NASDAQ:GPCR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.
91.8% of Structure Therapeutics shares are owned by institutional investors. 24.1% of Edgewise Therapeutics shares are owned by company insiders. Comparatively, 9.4% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Structure Therapeutics' return on equity of -29.09% beat Edgewise Therapeutics' return on equity.
Edgewise Therapeutics currently has a consensus price target of $31.20, indicating a potential upside of 81.82%. Structure Therapeutics has a consensus price target of $83.13, indicating a potential upside of 124.18%. Given Edgewise Therapeutics' higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Edgewise Therapeutics.
Edgewise Therapeutics received 4 more outperform votes than Structure Therapeutics when rated by MarketBeat users. However, 80.00% of users gave Structure Therapeutics an outperform vote while only 62.50% of users gave Edgewise Therapeutics an outperform vote.
Structure Therapeutics is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Structure Therapeutics had 6 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 9 mentions for Structure Therapeutics and 3 mentions for Edgewise Therapeutics. Structure Therapeutics' average media sentiment score of 1.84 beat Edgewise Therapeutics' score of 0.40 indicating that Edgewise Therapeutics is being referred to more favorably in the media.
Summary
Structure Therapeutics beats Edgewise Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Structure Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Structure Therapeutics Competitors List
Related Companies and Tools
